ClinicalTrials.gg
CompletedNCT06180954Updated Jan 13, 2025Results posted

A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants

A Phase 1 interventional study of [14C]-LOXO-305 and LOXO-305 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Sep 2020, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main purpose of this study is to evaluate the absorption, metabolism, and excretion (AME) profiles of pirtobrutinib (LOXO-305), to identify and characterize metabolites of pirtobrutinib (LOXO-305), and to assess the safety and tolerability of [14C] LOXO-305 in Part 1. To determine the absolute bioavailability of pirtobrutinib (LOXO-305), to evaluate the plasma concentration of total radioactivity, to evaluate the urinary excretion of [14C] LOXO-305 and total radioactivity, to evaluate the fecal excretion of [14C] LOXO-305 and total radioactivity, and to assess the safety and tolerability of pirtobrutinib (LOXO-305), and [14C] LOXO-305 in Part 2. Blood tests will be performed to check how much pirtobrutinib (LOXO-305) and [14C] LOXO-305 gets into the bloodstream and how long it takes the body to eliminate it.

The study will last up to approximately 60 days for Part 1 and approximately 47 days for Part 2.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²), inclusive
  • Male participants in good health, determined by no findings from medical history, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator
  • Participants who are capable of fathering a child must agree to use from the time of the dose administration through 6 months after the last dose of LOXO-305 administration
  • History of a minimum of 1 bowel movement per day

Exclusion criteria

Exclusion Criteria:

  • History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor
  • Positive serologic test for surface antigen (HBsAg), hepatitis B virus (HBV) core antibody, virus (HCV) antibody, or (HIV) antibody at Screening
  • Positive polymerase chain reaction (PCR) test for COVID-19 at Screening or Check-in (Day -1)
  • Known ongoing alcohol and/or drug abuse within 2 years prior to Screening
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee)
  • Part 1 only: Participation in a radiolabeled drug study where exposures are known to the Investigator (or designee) within the previous 4 months prior to Check-in (Day -1) or participation in a radiolabeled drug study where exposures are not known to the Investigator (or designee) within the previous 6 months prior to Check-in (Day -1).
  • Part 2 only: Participation in any other radiolabeled study drug trial within 12 months prior to Check-in (Day -1). Any previous radiolabeled study drug must have been received more than 12 months prior to Check-in (Day -1).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Part 1: [14C]-LOXO-305 Oral Solution

    Participants received a single dose of 200 milligram (mg) LOXO-305 radiolabelled with carbon-14, i.e., \[14C\]-LOXO-305 (approximately 200 microcurie radioactivity) administered as an oral solution.

    Drug: [14C]-LOXO-305

  • Experimental
    Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution

    Participants received: a single dose of 200 mg LOXO-305 administered as 2×100 mg oral tablets followed 2 hours later by a single dose of less than 100 microgram (μg) of \[14C\]-LOXO-305 (approximately 1 microcurie radioactivity) administered as an intravenous (IV) push over approximately 2 minutes.

    Drug: LOXO-305 · Drug: [14C]-LOXO-305

Interventions

  • Administered orally

    Also known as: LY3527727

  • Administered orally

    Also known as: Pirtobrutinib, LY3527727

  • Administered IV

    Also known as: LY3527727

06

What researchers measure

Primary outcomes

  1. Part 1: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

    AUC0-inf of LOXO-305 in plasma.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  2. Part 1: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

    AUC0-inf of total radioactivity in plasma and whole blood.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  3. Part 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

    AUC0-t of LOXO-305 in plasma.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  4. Part 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

    AUC0-t of total radioactivity in plasma and whole blood.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  5. Part 1: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

    Cmax of LOXO-305 in plasma.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  6. Part 1: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

    Cmax of total radioactivity in plasma and whole blood.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  7. Part 1: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

    Tmax of LOXO-305 in plasma.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  8. Part 1: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

    Tmax of total radioactivity in plasma and whole blood.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  9. Part 1: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

    t1/2 of LOXO-305 in plasma.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  10. Part 1: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

    t1/2 of total radioactivity in plasma and whole blood.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  11. Part 1: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

    CL/F of LOXO-305 in plasma.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  12. Part 1: PK: Apparent Volume of Distribution (Vz/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

    Vz/F of LOXO-305 in plasma.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  13. Part 1: PK: Ratio of AUC0-inf of Plasma LOXO-305 to AUC0-inf of Plasma Total Radioactivity

    AUC0-inf of plasma LOXO-305 relative to AUC0-inf of plasma total radioactivity, expressed in ratio.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  14. Part 1: PK: Ratio of AUC0-inf of Whole Blood Total Radioactivity to AUC0-inf of Plasma Total Radioactivity

    AUC0-inf of whole blood total radioactivity relative to AUC0-inf of plasma total radioactivity, expressed in ratio.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  15. Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Urine

    The urine sampling time points from pre-dose through 360 hours post-dose were used to assess this outcome.

    Time frame: Pre-dose, 0 (time of dose), 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  16. Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Feces

    The feces sampling time points from the 0 hour (i.e. time of dose) through 360 hours post-dose were used to assess this outcome.

    Time frame: 0 (time of dose), 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  17. Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces

    The feces sampling time points from the 0 hour (i.e. time of dose) through 360 hours post-dose were used to assess this outcome.

    Time frame: 0 (time of dose), 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  18. Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine

    The urine sampling time points from pre-dose through 360 hours post-dose were used to assess this outcome.

    Time frame: Pre-dose, 0 (time of dose), 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  19. Part 1: PK: Metabolic Profile of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

    The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in plasma using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.

    Time frame: 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264 h post-dose

  20. Part 1: PK: Metabolic Profile of LOXO-305 in Urine Following a Single Oral Dose of [14C]-LOXO-305

    The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in urine using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.

    Time frame: Pre-dose, 0 (time of dose), 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  21. Part 1: PK: Metabolic Profile of LOXO-305 in Feces Following a Single Oral Dose of [14C]-LOXO-305

    The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in feces using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.

    Time frame: 0 (time of dose), 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose

  22. Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma

    AUC0-inf of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  23. Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of [14C]-LOXO-305 in Plasma

    AUC0-inf of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  24. Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma

    AUC0-inf of total radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  25. Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma

    AUC0-t of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  26. Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of [14C]-LOXO-305 in Plasma

    AUC0-t of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  27. Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma

    AUC0-t of Total Radioactivity in Plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  28. Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma

    Cmax of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  29. Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of [14C]-LOXO-305 in Plasma

    Cmax of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  30. Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma

    Cmax of Total Radioactivity in Plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  31. Part 2: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma

    Tmax of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  32. Part 2: PK: Time to Maximum Observed Concentration (Tmax) of [14C]-LOXO-305 in Plasma

    Tmax of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  33. Part 2: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma

    Tmax of Total Radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  34. Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma

    t1/2 of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  35. Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of [14C]-LOXO-305 in Plasma

    t1/2 of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  36. Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma

    t1/2 of Total Radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  37. Part 2: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma

    CL/F of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  38. Part 2: PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of LOXO-305 in Plasma

    Vz/F of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  39. Part 2: PK: Absolute Bioavailability of LOXO-305 in Plasma

    The absolute bioavailability expressed in ratio was calculated using the formula= AUC0-inf (oral) x Dose (IV) divided by AUC0-inf (IV) x Dose (oral) . The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  40. Part 2: PK: Total Clearance (CL) of [14C]-LOXO-305 in Plasma

    CL of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  41. Part 2: PK: Volume of Distribution (Vz) of [14C]-LOXO-305 in Plasma

    Vz of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.

  42. Part 2: PK: Volume of Distribution at Steady State (Vss) of [14C]-LOXO-305 in Plasma

    Vss of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  43. Part 2: PK: Renal Clearance (CLR) of [14C]-LOXO-305

    CLR of \[14C\]-LOXO-305 in urine collection. The urine sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-IV dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  44. Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Urine

    The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  45. Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Urine

    The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  46. Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Feces

    The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.

    Time frame: 0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  47. Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Feces

    The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.

    Time frame: 0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  48. Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Urine

    The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  49. Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine

    The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  50. Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Feces

    The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.

    Time frame: 0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

  51. Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces

    The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.

    Time frame: 0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose

07

Results

Posted Jan 13, 2025

Participant flow

Participant flow — Overall Study
MilestonePart 1: [14C]-LOXO-305 Oral SolutionPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Started45
Received at least one dose of study drug.45
Completed45
Not completed00

Outcome measures

PrimaryPart 1: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

AUC0-inf of LOXO-305 in plasma.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · hours*nanogram per milliliter (h*ng/mL)
Part 1: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
hours*nanogram per milliliter (h*ng/mL)Part 1: [14C]-LOXO-305 Oral Solution
Part 1: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-30575300 ± 14.8
PrimaryPart 1: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

AUC0-inf of total radioactivity in plasma and whole blood.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · hours*nanogram equivalent per gram
Part 1: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
hours*nanogram equivalent per gramPart 1: [14C]-LOXO-305 Oral Solution
Plasma111000 ± 15.8
Whole Blood71200 ± 12.6
PrimaryPart 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

AUC0-t of LOXO-305 in plasma.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · hours*nanogram per milliliter (h*ng/mL)
Part 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
hours*nanogram per milliliter (h*ng/mL)Part 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-30574500 ± 14.9
PrimaryPart 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

AUC0-t of total radioactivity in plasma and whole blood.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · hours*nanogram equivalent per gram
Part 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
hours*nanogram equivalent per gramPart 1: [14C]-LOXO-305 Oral Solution
Plasma109000 ± 16.1
Whole Blood68900 ± 13
PrimaryPart 1: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

Cmax of LOXO-305 in plasma.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Part 1: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
nanograms per milliliter (ng/mL)Part 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-3053530 ± 8.8
PrimaryPart 1: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

Cmax of total radioactivity in plasma and whole blood.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · nanogram equivalent per gram
Part 1: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
nanogram equivalent per gramPart 1: [14C]-LOXO-305 Oral Solution
Plasma4280 ± 7.7
Whole Blood3020 ± 7.7
PrimaryPart 1: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

Tmax of LOXO-305 in plasma.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Median · hours
Part 1: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
hoursPart 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-3051.80 (1.5 to 3)
PrimaryPart 1: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

Tmax of total radioactivity in plasma and whole blood.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Median · hours
Part 1: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
hoursPart 1: [14C]-LOXO-305 Oral Solution
Plasma1.80 (1.50 to 4)
Whole Blood1.80 (1.50 to 3)
PrimaryPart 1: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

t1/2 of LOXO-305 in plasma.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Mean · hours
Part 1: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
hoursPart 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-30517.8 ± 2.26
PrimaryPart 1: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305

t1/2 of total radioactivity in plasma and whole blood.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Mean · hours
Part 1: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
hoursPart 1: [14C]-LOXO-305 Oral Solution
Plasma25.3 ± 4.76
Whole Blood21.7 ± 3.08
PrimaryPart 1: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

CL/F of LOXO-305 in plasma.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · liter per hour (L/h)
Part 1: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
liter per hour (L/h)Part 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-3052.69 ± 15.8
PrimaryPart 1: PK: Apparent Volume of Distribution (Vz/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

Vz/F of LOXO-305 in plasma.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · liter (L)
Part 1: PK: Apparent Volume of Distribution (Vz/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
liter (L)Part 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Apparent Volume of Distribution (Vz/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-30568.8 ± 21
PrimaryPart 1: PK: Ratio of AUC0-inf of Plasma LOXO-305 to AUC0-inf of Plasma Total Radioactivity

AUC0-inf of plasma LOXO-305 relative to AUC0-inf of plasma total radioactivity, expressed in ratio.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · ratio
Part 1: PK: Ratio of AUC0-inf of Plasma LOXO-305 to AUC0-inf of Plasma Total Radioactivity
ratioPart 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Ratio of AUC0-inf of Plasma LOXO-305 to AUC0-inf of Plasma Total Radioactivity0.680 ± 1.2
PrimaryPart 1: PK: Ratio of AUC0-inf of Whole Blood Total Radioactivity to AUC0-inf of Plasma Total Radioactivity

AUC0-inf of whole blood total radioactivity relative to AUC0-inf of plasma total radioactivity, expressed in ratio.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Geometric mean · ratio
Part 1: PK: Ratio of AUC0-inf of Whole Blood Total Radioactivity to AUC0-inf of Plasma Total Radioactivity
ratioPart 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Ratio of AUC0-inf of Whole Blood Total Radioactivity to AUC0-inf of Plasma Total Radioactivity0.642 ± 3.4
PrimaryPart 1: PK: Cumulative Amount of Total Radioactivity Excreted in Urine

The urine sampling time points from pre-dose through 360 hours post-dose were used to assess this outcome.

Time frame:
Pre-dose, 0 (time of dose), 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Mean · milligram equivalent (mg eq)
Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Urine
milligram equivalent (mg eq)Part 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Urine116 ± 4.05
PrimaryPart 1: PK: Cumulative Amount of Total Radioactivity Excreted in Feces

The feces sampling time points from the 0 hour (i.e. time of dose) through 360 hours post-dose were used to assess this outcome.

Time frame:
0 (time of dose), 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Mean · milligram equivalent (mg eq)
Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Feces
milligram equivalent (mg eq)Part 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Feces75.5 ± 5.29
PrimaryPart 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces

The feces sampling time points from the 0 hour (i.e. time of dose) through 360 hours post-dose were used to assess this outcome.

Time frame:
0 (time of dose), 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Mean · percentage of total radioactivity
Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces
percentage of total radioactivityPart 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces37.3 ± 2.31
PrimaryPart 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine

The urine sampling time points from pre-dose through 360 hours post-dose were used to assess this outcome.

Time frame:
Pre-dose, 0 (time of dose), 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Mean · percentage of total radioactivity
Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine
percentage of total radioactivityPart 1: [14C]-LOXO-305 Oral Solution
Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine57 ± 2.16
PrimaryPart 1: PK: Metabolic Profile of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305

The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in plasma using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.

Time frame:
1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264 h post-dose
Reported as:
Number · sample positive
Part 1: PK: Metabolic Profile of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
sample positivePart 1: [14C]-LOXO-305 Oral Solution
Loxo-3051
M11
M21
M30
M41
M110
M120
M150
M160
M170
M180
M190
M200
M210
M220
PrimaryPart 1: PK: Metabolic Profile of LOXO-305 in Urine Following a Single Oral Dose of [14C]-LOXO-305

The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in urine using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.

Time frame:
Pre-dose, 0 (time of dose), 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Number · sample positive
Part 1: PK: Metabolic Profile of LOXO-305 in Urine Following a Single Oral Dose of [14C]-LOXO-305
sample positivePart 1: [14C]-LOXO-305 Oral Solution
Loxo-3051
M10
M21
M31
M41
M110
M121
M151
M161
M171
M181
M191
M200
M210
M220
PrimaryPart 1: PK: Metabolic Profile of LOXO-305 in Feces Following a Single Oral Dose of [14C]-LOXO-305

The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in feces using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.

Time frame:
0 (time of dose), 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Reported as:
Number · sample positive
Part 1: PK: Metabolic Profile of LOXO-305 in Feces Following a Single Oral Dose of [14C]-LOXO-305
sample positivePart 1: [14C]-LOXO-305 Oral Solution
Loxo-3051
M10
M20
M30
M40
M111
M120
M150
M161
M170
M180
M190
M201
M211
M221
PrimaryPart 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma

AUC0-inf of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Geometric mean · hours*nanogram per milliliter (h*ng/mL)
Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma
hours*nanogram per milliliter (h*ng/mL)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma105000 ± 28.1
PrimaryPart 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of [14C]-LOXO-305 in Plasma

AUC0-inf of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Geometric mean · hours*picogram per milliliter
Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of [14C]-LOXO-305 in Plasma
hours*picogram per milliliterPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of [14C]-LOXO-305 in Plasma13700 ± 29
PrimaryPart 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma

AUC0-inf of total radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Geometric mean · hours*picogram equivalent per milliliter
Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma
hours*picogram equivalent per milliliterPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma18300 ± 25.2
PrimaryPart 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma

AUC0-t of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · hours*nanogram per milliliter (h*ng/mL)
Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma
hours*nanogram per milliliter (h*ng/mL)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma104000 ± 28.7
PrimaryPart 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of [14C]-LOXO-305 in Plasma

AUC0-t of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Geometric mean · hours*picogram per milliliter
Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of [14C]-LOXO-305 in Plasma
hours*picogram per milliliterPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of [14C]-LOXO-305 in Plasma13700 ± 29.2
PrimaryPart 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma

AUC0-t of Total Radioactivity in Plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Geometric mean · hours*picogram equivalent per milliliter
Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma
hours*picogram equivalent per milliliterPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma18000 ± 25.8
PrimaryPart 2: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma

Cmax of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma
nanograms per milliliter (ng/mL)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma4490 ± 19.2
PrimaryPart 2: PK: Maximum Observed Plasma Concentration (Cmax) of [14C]-LOXO-305 in Plasma

Cmax of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Geometric mean · picogram per milliliter (pg/mL)
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of [14C]-LOXO-305 in Plasma
picogram per milliliter (pg/mL)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of [14C]-LOXO-305 in Plasma994 ± 31.6
PrimaryPart 2: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma

Cmax of Total Radioactivity in Plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Geometric mean · picogram equivalent per milliliter
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma
picogram equivalent per milliliterPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma1110 ± 53.1
PrimaryPart 2: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma

Tmax of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Median · hours
Part 2: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma
hoursPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma5.00 (2.03 to 5)
PrimaryPart 2: PK: Time to Maximum Observed Concentration (Tmax) of [14C]-LOXO-305 in Plasma

Tmax of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Median · hours
Part 2: PK: Time to Maximum Observed Concentration (Tmax) of [14C]-LOXO-305 in Plasma
hoursPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Time to Maximum Observed Concentration (Tmax) of [14C]-LOXO-305 in Plasma0.167 (0.0333 to 12)
PrimaryPart 2: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma

Tmax of Total Radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Median · hours
Part 2: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma
hoursPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma0.167 (0.0333 to 0.167)
PrimaryPart 2: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma

t1/2 of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Mean · hours
Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma
hoursPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma18.7 ± 1.68
PrimaryPart 2: PK: Apparent Terminal Elimination Half-life (t1/2) of [14C]-LOXO-305 in Plasma

t1/2 of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Mean · hours
Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of [14C]-LOXO-305 in Plasma
hoursPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of [14C]-LOXO-305 in Plasma17.6 ± 1.24
PrimaryPart 2: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma

t1/2 of Total Radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Mean · hours
Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma
hoursPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma37.4 ± 9.72
PrimaryPart 2: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma

CL/F of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · liter per hour (L/h)
Part 2: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma
liter per hour (L/h)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma1.90 ± 28.1
PrimaryPart 2: PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of LOXO-305 in Plasma

Vz/F of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · liter (L)
Part 2: PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of LOXO-305 in Plasma
liter (L)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of LOXO-305 in Plasma51.0 ± 23.6
PrimaryPart 2: PK: Absolute Bioavailability of LOXO-305 in Plasma

The absolute bioavailability expressed in ratio was calculated using the formula= AUC0-inf (oral) x Dose (IV) divided by AUC0-inf (IV) x Dose (oral) . The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · ratio
Part 2: PK: Absolute Bioavailability of LOXO-305 in Plasma
ratioPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Absolute Bioavailability of LOXO-305 in Plasma0.855 ± 7.2
PrimaryPart 2: PK: Total Clearance (CL) of [14C]-LOXO-305 in Plasma

CL of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Geometric mean · liter per hour (L/h)
Part 2: PK: Total Clearance (CL) of [14C]-LOXO-305 in Plasma
liter per hour (L/h)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Total Clearance (CL) of [14C]-LOXO-305 in Plasma1.63 ± 29.7
PrimaryPart 2: PK: Volume of Distribution (Vz) of [14C]-LOXO-305 in Plasma

Vz of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Reported as:
Geometric mean · liter (L)
Part 2: PK: Volume of Distribution (Vz) of [14C]-LOXO-305 in Plasma
liter (L)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Volume of Distribution (Vz) of [14C]-LOXO-305 in Plasma41.2 ± 29
PrimaryPart 2: PK: Volume of Distribution at Steady State (Vss) of [14C]-LOXO-305 in Plasma

Vss of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · liter (L)
Part 2: PK: Volume of Distribution at Steady State (Vss) of [14C]-LOXO-305 in Plasma
liter (L)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Volume of Distribution at Steady State (Vss) of [14C]-LOXO-305 in Plasma36.3 ± 24.2
PrimaryPart 2: PK: Renal Clearance (CLR) of [14C]-LOXO-305

CLR of \[14C\]-LOXO-305 in urine collection. The urine sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-IV dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · liter per hour (L/h)
Part 2: PK: Renal Clearance (CLR) of [14C]-LOXO-305
liter per hour (L/h)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Renal Clearance (CLR) of [14C]-LOXO-3050.116 ± 36.8
PrimaryPart 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Urine

The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · microgram (μg)
Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Urine
microgram (μg)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Urine1.59 ± 28.3
PrimaryPart 2: PK: Cumulative Amount of Total Radioactivity Excreted in Urine

The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · microgram equivalent (μg eq)
Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Urine
microgram equivalent (μg eq)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Urine14.1 ± 11.4
PrimaryPart 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Feces

The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.

Time frame:
0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · microgram (μg)
Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Feces
microgram (μg)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Feces3.02 ± 40.5
PrimaryPart 2: PK: Cumulative Amount of Total Radioactivity Excreted in Feces

The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.

Time frame:
0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · microgram equivalent (μg eq)
Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Feces
microgram equivalent (μg eq)Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Feces4.97 ± 38.4
PrimaryPart 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Urine

The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · percentage of [14C]-LOXO-305
Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Urine
percentage of [14C]-LOXO-305Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Urine7.12 ± 28.9
PrimaryPart 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine

The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · percentage of total radioactivity
Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine
percentage of total radioactivityPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine63.1 ± 11.2
PrimaryPart 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Feces

The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.

Time frame:
0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · percentage of [14C]-LOXO-305
Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Feces
percentage of [14C]-LOXO-305Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Feces13.5 ± 40.5
PrimaryPart 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces

The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.

Time frame:
0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Reported as:
Geometric mean · percentage of total radioactivity
Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces
percentage of total radioactivityPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces22.3 ± 38.8

Adverse events

Collected over Part 1: Baseline up to Day 29; Part 2: Baseline up to Day 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: [14C]-LOXO-305 Oral Solution0/4 (0%)0/4 (0%)3/4 (75%)
Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution0/5 (0%)0/5 (0%)4/5 (80%)
Most frequent other events
Most frequent other events
EventPart 1: [14C]-LOXO-305 Oral SolutionPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution
Post procedural contusionInjury, poisoning and procedural complications0/43/5
Procedural painInjury, poisoning and procedural complications0/42/5
DiarrhoeaGastrointestinal disorders1/41/5
Skin abrasionInjury, poisoning and procedural complications1/40/5
HeadacheNervous system disorders1/40/5
EpistaxisRespiratory, thoracic and mediastinal disorders1/40/5
PapuleSkin and subcutaneous tissue disorders1/40/5
Skin lacerationInjury, poisoning and procedural complications0/41/5
Heart rate increasedInvestigations0/41/5

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Part 1: [14C]-LOXO-305 Oral SolutionPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV SolutionTotal
Mean39.5 ± 3.4224 ± 5.1530.9 ± 9.18
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: [14C]-LOXO-305 Oral SolutionPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV SolutionTotal
Female000
Male459
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: [14C]-LOXO-305 Oral SolutionPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV SolutionTotal
Hispanic or Latino011
Not Hispanic or Latino448
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: [14C]-LOXO-305 Oral SolutionPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV SolutionTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White347
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Part 1: [14C]-LOXO-305 Oral SolutionPart 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV SolutionTotal
United States459
08

Study locations

1 site
  • Covance Clinical Research Unit
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2020, 1 month.

Results were first posted in Jan 2025, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 26, 2023
StartActual
Sep 23, 2020
Primary completionActual
Nov 6, 2020
CompletionActual
Nov 6, 2020
Results first posted
Jan 13, 2025
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06180954
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Sep 23, 2020
Primary completion
Nov 6, 2020
Completion
Nov 6, 2020
Results posted
Jan 13, 2025
Last update
Jan 13, 2025

Study contacts

Renee Ward, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion